Markers of neural degeneration and regeneration in Down syndrome patients

Egyptian Journal of Medical Human Genetics

Volumn 14, Issue 1, 2013, Pages 49-53

  Abdel Meguid, Iman Ehsan ^a   Abdel Salam, Ekram ^a   Latif, Doaa M Abdel ^b   Korraa, Soheir ^c   Ismaiel, Amal ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b Al Azhar University   (Egypt)

^c NATIONAL CENTER FOR RADIATION RESEARCH AND TECHNOLOGY   (Egypt)

Author keywords

Advanced glycation end products receptors; CD34; Down syndrome; Nestin

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN[1-42]; CD34 ANTIGEN; MESSENGER RNA; NESTIN;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN SYNDROME; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; MONONUCLEAR CELL; NERVE CELL DEGENERATION; NERVE FIBER REGENERATION; PRESCHOOL CHILD; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SCHOOL CHILD;

EID: 84900367216     PISSN: 11108630     EISSN: 20902441     Source Type: Journal    
DOI: 10.1016/j.ejmhg.2012.08.008     Document Type: Article

References (43)

1. Gladzicki Z., Siarey R., Pearce R., Stoll J., Rapoport S. The cause of mental retardation in Down syndrome: extrapolation from full and segmental trisomy 16 mouse models. Brain Res Brain Res Rev 2001, 35:115-145.
2. Rahmani Z., Blouin J.L., Creau-Goldberg N., Watkins P.C., Mattei J.F., Poissonnier M., et al. Critical role of the D21S55 region on chromosome 21 in the pathogenesis of Down syndrome. Proc Natl Acad Sci USA 1989, 86:5958-5962.
3. Fuentes J., Genescà L., Kingsbury T., Cunningham K., Pérez-Riba M., Estivill X., et al. Hum Mol Genet 2000, 9:1681-1690.
4. Tanzi R.E., Gusella J., Watkins P., Bruns G., George-Hyslop P. Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 1987, 235:880-884.
5. Goldgaber D., Lerman M.I., McBride O.W., Saffiotti U., Gajdusek D. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. Science 1987, 235:877-880.
6. Robakis N.K., Wisniewski H.M., Jenkins E.C., Devine-Gage E.A., Houck G. Chromosome 21q21 sublocalisation of gene encoding beta-amyloid peptide in cerebral vessels and neuritic (senile) plaques of people with Alzheimer disease and Down syndrome. Lancet 1987, 1:384-385.
7. Wisniewski K.E., Wisniewski H.M., Wen G. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol 1985, 17:278-282.
8. Wavrant-De Vrièze F., Crook R., Holmans P., Kehoe P., Owen M. Genetic variability at the amyloid-[beta] precursor protein locus may contribute to the risk of late-onset Alzheimer's disease. Neurosci Lett 1999, 269:67-70.
9. Lott I.T., Head E. Alzheimer disease and Down syndrome: factors in pathogenesis. Neurobiol Aging 2005, 26:383-389.
10. Lagasse E., Connors H., Al-Dhalimy M., Reitsma M., Dohse M., Osborne L., et al. Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med 2000, 6(11):1229-1234.
11. Brazelton T.R., Rossi F.M., Keshet G.I., Blau H.M. From marrow to brain: expression of neuronal phenotypes in adult mice. Science 2000, 290(5497):1775-1779.
12. Mezey E., Chandross K. Bone marrow: a possible alternative source of cells in the adult nervous system. Eur J Pharmacol 2000, 405:297-302.
13. Kucia M., Zhang Y., Reca R., Wysoczynski M., Machalinski B., Majka M., et al. Cells enriched in markers of neural tissue-committed stem cells reside in the bone marrow and are mobilized into the peripheral blood following stroke. Leukemia 2006, 20(1):18-28.
14. Abd El-Salam E., Abdel-Meguid I., Korraa S.S. Assessment of markers of oxidative stress and antioxidant enzymes in Egyptian Down syndrome patients. Ekram Abdel Salam, ImanBdel-Meguid and SoheirKorraThe Gaz. Egypt Paed 2001, 49(3):271-278.
15. Sinet P. Metabolism of oxygen derivatives in Down's syndrome. Ann N Y Acad Sci 1982, 396:83-94.
16. Tanji N., Markowitz G.S., Fu C., Kislinger T., Taguchi A., Pischetsrieder M., et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2000, 11:1656-1666.
17. Nakamura E., Tanaka S. Biological ages of adult men and women with Down's syndrome and its changes with ageing. Mech Ageing Dev 1998, 105(1-2):89-103.
18. Xia W., Yang T., Shankar G., Smith I., Shen Y., Walsh D.M., et al. A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol 2009, 66(2):190-199.
19. Duda D.G., Cohen K.S., Scadden D.T., Jain R. A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. Nat Protoc 2007, 2(4):805-810.
20. Wisniewski K., Wisniewski H., Wen G. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol 1985, 17:278-286.
21. Hoeffer C., Dey A., Sachan N., Wong H., Patterson R.J., Shelton J., et al. The Down syndrome Critical Region protein RCAN1 regulates long-term potentiation and memory via inhibition of phosphatase signaling. J Neurosci 2007, 27(48). 13161-1372.
22. Sakata N., Imanaga Y., Meng J., Tachikawa Y., Takebayashi S., Nagai R., et al. Immunohistochemical localization of different epitopes of advanced glycation end products in human atherosclerotic lesions. Atherosclerosis 1998, 141:61-75.
23. Odetti P., Angelini G., Dapino D., Zaccheo D., Garibaldi S., Dagna-Bricarelli F., et al. Early glycoxidation damage in brains from Down's syndrome. Biochem Biophys Res Commun 1998, 243(3):849-851.
24. Robakis K., Wisniewski H., Jenkins E., Devine-Gage E., Houck G. Chromosome 21q21 sublocalisation of gene encoding beta-amyloid peptide in cerebral vessels and neuritic (senile) plaques of people with Alzheimer disease and Down syndrome. Lancet 1987, 1:384-385.
25. Prasher V.P., Sajith S.G., Mehta P., Zigman W.B., Schupf N. Plasma beta amyloid and duration of Alzheimer's disease in adults with Down syndrome. Int J Geriatr Psychiatry 2010, 25(2):202-207.
26. Schupf N., Patel B., Pang D., Zigman W.B., Silverman W., Mehta P.D., et al. Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome. Arch Neurol 2007, 64(7):1007-1013.
27. Rovelet-Lecrux A., Hannequin D., Raux G., Le Meur N., Laquerriere A. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 2006, 38:24-26.
28. Wavrant D., Vrièze F., Crook R., Holmans P., Kehoe P., Owen M. Genetic variability at the amyloid-[beta] precursor protein locus may contribute to the risk of late-onset Alzheimer's disease. Neurosci Lett 1999, 269:67-70.
29. Prasher V., Sajith S., Mehta P., Zigman W., Schupf N. Plasma beta amyloid and duration of Alzheimer's disease in adults with Down syndrome. Int J Geriatr Psychiatry 2010, 25(2):202-207.
30. Schupf N., Patel B., Pang D., Zigman W.B., Silverman W., Mehta P.D., et al. Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome. Arch Neurol 2007, 64(7):1007-1013.
31. Rensink A.A., de Waal R.M., Kremer B., Verbeek M.M. Pathogenesis of cerebral amyloid angiopathy. Brain Res Brain Res Rev 2003, 43:207-223.
32. Weller R., Subash M., Preston S., Mazanti I., Carare R. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol 2008, 18:253-266.
33. Nagababu E., Usatyuk E., Enika P., Viswanathan Natarajan V., Rifkind J. Vascular endothelial barrier dysfunction mediated by amyloid-β proteins. J Alzheimers Dis 2009, 17(4):845-854.
34. van Vliet E.A., da Costa Araújo S., Redeker S., van Schaik R., Aronica E., Gorter J.A. Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain 2007, 130(Pt 2):521-534.
35. Jablonska B., Ford D., Trisler D., Pessac B. The growth capacity of bone marrow CD34 positive cells in culture is drastically reduced in a murine model of Down syndrome. C R Biol 2006, 329(9):726-732.
36. Iwasaki H., Kawamoto A., Ishikawa M., et al. Dose-dependent contribution of CD34-positive cell transplantation to concurrent vasculogenesis and cardiomyogenesis for functional regenerative recovery after myocardial infarction. Circulation 2006, 113:1311-1325.
37. Badorff C., Brandes R., Popp R., Rupp S., Urblish C., Aicher A., et al. Transdifferentiation of blood-derived human adult endothelial progenitor cells into functionally active cardiomyocytes. Circulation 2003, 107:1024-1032.
38. Hewitt C., Ling K., Merson T., Simpson K., Ritchie M., King S., et al. Gene network disruptions and neurogenesis defects in the adult Ts1Cje mouse model of Down syndrome. PLoS One 2010, 5(7):e11561.
39. Porayette P., Gallego M., Kaltcheva M., Bowen R., Meethal V., Atwood C. Differential processing of amyloid-β precursor protein directs human embryonic stem cell proliferation and differentiation into neuronal precursor cells. J Biol Chem 2009, 284(35):23806-23817.
40. Whittle N., Sartori S., Dierssen M., Lubec G., Singewald N. Fetal Down syndrome brains exhibit aberrant levels of neurotransmitters critical for normal brain development, APPNEWS. Paediatrics 2007, 120(6):1465-1471.
41. Wisniewski k. Down syndrome children often have brain with maturation delay, retardation of growth, and cortical dysgenesis. Am J Med Genet Suppl 1990, 37(7):274-281.
42. Golden J., Hyman B. Development of the superior temporal neocortex is anomalous in trisomy 21. J Neuropathol Exp Neurol 1994, 53:513-520.
43. Wisniewski K., Laure-Kamionowska M., Wisniewski H. Evidence of arrest of neurogenesis and synaptogenesis in brains of patients with Down's syndrome. N Engl J Med 1984, 311(18):1187-1188.